Cargando…
CD166-specific CAR-T cells potently target colorectal cancer cells
Chimeric antigen receptor (CAR) T-cell therapy is emerging as an effective cancer treatment, such as for hematological malignancies, however its effectiveness as an approach to treat solid tumors, such as in colorectal cancer (CRC), remains to be better developed. One area of intense development has...
Autores principales: | He, Shuai, Li, Shirong, Guo, Jing, Zeng, Xiaozhu, Liang, Dandan, Zhu, Yongjie, Li, Yi, Yang, Dong, Zhao, Xudong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Neoplasia Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9637812/ https://www.ncbi.nlm.nih.gov/pubmed/36327697 http://dx.doi.org/10.1016/j.tranon.2022.101575 |
Ejemplares similares
-
Humanized CD30-Targeted Chimeric Antigen Receptor T Cells Exhibit Potent Preclinical Activity Against Hodgkin’s Lymphoma Cells
por: Guo, Jing, et al.
Publicado: (2022) -
Association of CD166 expression with clinicopathologic characteristics of colorectal cancer
por: Moslemi, Dariush, et al.
Publicado: (2016) -
CD171- and GD2-specific CAR-T cells potently target retinoblastoma cells in preclinical in vitro testing
por: Andersch, Lena, et al.
Publicado: (2019) -
Hotspot KRAS exon 2 mutations in CD166 positive colorectal cancer and colorectal adenoma cells
por: Wong, Hung Lai, et al.
Publicado: (2018) -
ANGI-03 Functional roles of CD166/activated leukocyte cell adhesion molecule (CD166/ALCAM) for glioblastoma invasion
por: Kijima, Noriyuki, et al.
Publicado: (2020)